Observational studyObesity surgery2026
Gut Microbiota-specific Profile Prior to Surgery for Predicting Type 2 Diabetes Remission in Patients Undergoing Sleeve Gastrectomy.
Observational study in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe predictive role of baseline gut microbiota in type 2 diabetes (T2D) remission after bariatric surgery remains unexplored. This study aimed to identify specific gut microbiota profiles prior to surgery associated with T2D remission following sleeve gastrectomy (SG).
methodsThis was an observational study including participants with a body mass index (BMI) ≥ 40 kg/m2 and T2D who underwent SG, and had preoperative stool samples available. Gut microbiota was analayzed by 16 S rRNA sequencing. Participants were classified into remission and non-remission groups based on T2D status one year after SG.
resultsA total of forty-six participants were included. After adjusting for baseline confounders (i.e., age, HbA1c levels, T2D duration, and insulin treatment), preoperative gut microbiota diversity showed no statistically significant differences between groups, except for Pielou’s evenness index, which was significantly higher in the non-remission group (p = 0.01). ANCOM-BC2 analysis identified an enrichment in Fusicatenibacter, Holdemanella and Senegalimassilia in the non-remission group, whereas Eggerthella, Flavonifractor, Ruminococcaceae g__Incertae Sedis and Ruminococcus gnavus group were enriched in the remission group. Furthermore, insulin treatment and the gut microbial taxa Ruminococcaceae g__Incertae Sedis, Fusicatenibacter, and Eggerthella emerged as potential predictors of T2D remission. Functional analysis using PICRUSt2 revealed increased carbohydrate metabolism pathways in the remission group.
conclusionsBaseline gut microbiota composition may serve as an independent predictor of T2D remission in patients undergoing SG, and could become a potentially relevant biomarker, complementing other existing clinical predictors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.